These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34164266)

  • 21. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
    Gao G; Qiao M; Liu H; Jiang T; Zhou F; Li X; Zhao C; Chen X; Su C; Ren S; Zhou C
    J Thorac Dis; 2019 Sep; 11(9):3794-3807. PubMed ID: 31656652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy.
    Shi Y; Liu X; Du J; Zhang D; Liu J; Chen M; Zhao J; Zhong W; Xu Y; Wang M
    Thorac Cancer; 2022 Jan; 13(2):219-227. PubMed ID: 34825500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
    Mark NM; Kargl J; Busch SE; Yang GHY; Metz HE; Zhang H; Hubbard JJ; Pipavath SNJ; Madtes DK; Houghton AM
    Am J Respir Crit Care Med; 2018 Feb; 197(3):325-336. PubMed ID: 28934595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
    Gao G; Jia K; Zhao S; Li X; Zhao C; Jiang T; Su C; Ren S; Zhou F; Zhou C
    Transl Lung Cancer Res; 2019 Dec; 8(6):920-928. PubMed ID: 32010570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.
    Minami S; Ihara S; Tanaka T; Komuta K
    World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
    Wu M; Zhu Y; Chen X; Wang X; Lin X; Yan X; Mo P; Ye Y; Zeng Y; Yang Y; Fu Z
    J Gastrointest Oncol; 2023 Feb; 14(1):54-63. PubMed ID: 36915449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis.
    Kim Y; Koh JS; Woo SD; Lee SI; Kang DH; Park D; Chung C; Kwon IS; Lee JE
    Clin Med Insights Oncol; 2022; 16():11795549221139522. PubMed ID: 36532699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
    Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; Master VA; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Bilen MA
    Invest New Drugs; 2019 Dec; 37(6):1198-1206. PubMed ID: 30725388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor.
    Chen Y; Zhang C; Peng Z; Qi C; Gong J; Zhang X; Li J; Shen L
    Front Oncol; 2021; 11():589022. PubMed ID: 34141607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment.
    Tong J; Mao Y; Yang Z; Xu Q; Zheng Z; Zhang H; Wang J; Zhang S; Rong W; Zheng L
    Cancer Manag Res; 2021; 13():4041-4053. PubMed ID: 34040444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
    Lang D; Brauner A; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Kaiser B; Greil R; Lamprecht B
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.